<DOC>
	<DOCNO>NCT02317016</DOCNO>
	<brief_summary>This Phase I , open-label , 2-part study patient confirm diagnosis epidermal growth factor receptor ( EGFR ) mutation positive ( EGFRm+ ) non-small cell lung cancer ( NSCLC ) , progress follow prior therapy approve EGFR tyrosine kinase inhibitor ( TKI ) agent . Part A assess effect AZD9291 pharmacokinetic ( PK ) parameter rosuvastatin , follow multiple oral dose AZD9291 fast state . Part B allow patient access AZD9291 PK phase ( Part A ) provide additional safety data collection . All patient Part A complete treatment may continue receive AZD9291 80 mg daily single agent : disease progression ; longer derive clinical benefit ; reason .</brief_summary>
	<brief_title>Study Assess Effect AZD9291 Blood Levels Rosuvastatin , Patients With EGFRm+ Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Osimertinib</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>For inclusion study patient must fulfil follow criterion : 1 . Male female , age least 18 year . 2 . Histological cytological confirmation diagnosis NSCLC . 3 . Radiological documentation disease progression previous continuous treatment EGFR TKI , eg , gefitinib , erlotinib afatinib . In addition , line therapy may give . All patient must document radiological progression last treatment administer prior enrol study . 4 . Confirmation tumour harbour EGFR mutation know associated EGFR TKI sensitivity ( include G719X , exon 19 deletion , L858R , L861Q ) . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 deterioration previous 2 week ( Appendix G ) . 6 . Patients must life expectancy â‰¥12 week estimate time screening . 7 . Females use adequate contraceptive measure must negative pregnancy test prior start dose childbearing potential , must evidence nonchildbearing potential fulfil one follow criterion screen : Postmenopausal define age 50 year amenorrhoeic least 12 month follow cessation exogenous hormonal treatment ; Women 50 year old would consider postmenopausal amenorrhoeic 12 month follow cessation exogenous hormonal treatment luteinising hormone ( LH ) follicle stimulate hormone ( FSH ) level postmenopausal range institution ; Documentation irreversible surgical sterilisation hysterectomy , bilateral oophorectomy , bilateral salpingectomy , tubal ligation . 8 . Patients willing able comply protocol duration study include undergoing treatment schedule visit examination . 9 . Male patient willing use barrier contraception , ie , condom . Exlusion Criteria : 1 . Participation another clinical study IP last 14 day ( longer depend defined characteristic agent use ) . 2 . Any patient Asian ethnicity parent Asian ethnicity ( eg , Chinese , Filipino , Japanese , Korean Vietnamese ) . If grandparent Asian , acceptable . Asian Indians acceptable . 3 . Treatment w/ follow : EGFR TKI ( eg , erlotinib , gefitinib afatinib ) within 8 day approx . 5 x halflife , whichever longer , first dose study treatment ; Any cytotoxic chemotherapy , investigational agent anticancer drug previous treatment regimen clinical study within 14 day first dose study treatment ; Major surgery ( exclude placement vascular access ) w/in 4 week 1st dose study treatment ; Radiotherapy limit field radiation palliation w/in 1 week first dose study treatment , exception patient receive radiation 30 % bone marrow wide field radiation must complete w/in 4 week 1st dose study treatment ; Patients currently receive ( unable stop use prior receiving first dose study treatment ) medication herbal supplement know potent inhibitor CYP3A4 ( least 1 week prior ) potent inducer CYP3A4 ( least 3 week prior ) . All patient must avoid concomitant use medication , herbal supplement and/or ingestion food know inducer/inhibitory effect CYP3A4 . 4 . Unresolved toxicity prior therapy &gt; CTCAE Grade 1 study start besides alopecia Grade 2 , prior platinumtherapy relate neuropathy . 5 . Any intake grapefruit , grapefruit juice , Seville oranges , Seville orange marmalade , product contain grapefruit Seville oranges within 7 day first administration IP final PK sample collection Day 35 Part A . 6 . Spinal cord compression brain metastasis unless asymptomatic , stable require steroid least 4 week prior start study treatment . 7 . Any evidence severe uncontrolled systemic disease , include uncontrolled hypertension active bleeding diatheses , PI 's opinion make undesirable patient participate study would jeopardise compliance protocol , active infection include hep B , hep C HIV . Screening chronic condition require . 8 . Inadequate bone marrow reserve organ function demonstrate follow laboratory value : ANC &lt; 1.5 x 10^9/L ; Platelet count &lt; 100 x 10^9/L ; Haemoglobin &lt; 90 g/L ; ALT &gt; 2.5 time ULN demonstrable liver metastasis &gt; 5 time ULN presence liver metastases ; AST &gt; 2.5 time ULN demonstrable liver metastasis &gt; 5 time ULN presence liver metastases ; Total bilirubin &gt; 1.5 time ULN liver metastases &gt; 3 time ULN presence document Gilbert 's Syndrome ( unconjugated hyperbilirubinaemia ) liver metastasis ; Creatinine &gt; 1.5 time ULN concurrent creatinine clearance &lt; 50 mL/min ( measure calculate Cockcroft Gault equation ) ; confirmation creatinine clearance require creatinine &gt; 1.5 time ULN . 9 . Any following cardiac criterion : Mean rest correct QT interval correct heart rate use Fridericia 's correction factor ( QTcF ) &gt; 470 msec obtain 3 ECGs ; Any clinically important abnormality rhythm , conduction morphology rest ECG eg , complete leave bundle branch block , third degree heart block , second degree heart block , PR interval &gt; 250 msec ; Any factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalaemia , congenital long QT syndrome , family history long QT syndrome unexplained sudden death 40 year age concomitant medication know prolong QT interval 10 . Patients unable swallow orally administer medication patient gastrointestinal disorder significant gastrointestinal resection likely interfere absorption AZD9291 . 11 . Past medical history ILD , druginduced ILD , radiation pneumonitis require steroid treatment , evidence clinically active ILD . 12 . Women breastfeed . 13 . Patients know hypersensitivity AZD9291 rosuvastatin excipients product . 14 . Concomitant medication contraindicate use rosuvastatin due drug interaction and/or associate increase risk rhabdomyolysis ( include , limited ) : fibrates ( eg , gemfibrozil , fenofibrate ) , niacin , cyclosporine , lopinavir/ritonavir atazanavir/ritonavir colchinine . 15 . Past medical history drugrelated rhabdomyolysis and/or myalgia . 16 . Use 3hydroxy3methylglutaryl coenzyme Areductase inhibitor , lovastatin simvastatin ( Part A ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>oncology</keyword>
	<keyword>cancer</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>anticancer drug</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>AZD9291</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>EGFR gene</keyword>
</DOC>